| Primary |
| Coronary Artery Disease |
35.1% |
| Prophylaxis |
12.3% |
| Atrial Fibrillation |
7.0% |
| Stroke |
7.0% |
| Cerebrovascular Accident Prophylaxis |
5.3% |
| Pain |
5.3% |
| Arthritic Pains |
3.5% |
| Pulmonary Embolism |
3.5% |
| Anxiety |
1.8% |
| Arthritis |
1.8% |
| Atrial Flutter |
1.8% |
| Cardiovascular Event Prophylaxis |
1.8% |
| Cerebrovascular Accident |
1.8% |
| Chronic Back Pain |
1.8% |
| Coronary Arterial Stent Insertion |
1.8% |
| Deep Vein Thrombosis |
1.8% |
| Hypertension |
1.8% |
| Neck Pain |
1.8% |
| Osteoarthritis |
1.8% |
| Peripheral Arterial Disease |
1.8% |
|
| Upper Gastrointestinal Haemorrhage |
26.3% |
| Rectal Haemorrhage |
10.5% |
| Syncope |
7.9% |
| Haemorrhagic Anaemia |
5.3% |
| Large Intestine Polyp |
5.3% |
| Occult Blood Positive |
5.3% |
| Tachycardia |
5.3% |
| Atrial Fibrillation |
2.6% |
| Cardiac Failure |
2.6% |
| Gastric Haemorrhage |
2.6% |
| Gastric Ulcer |
2.6% |
| Gastritis |
2.6% |
| Gastrointestinal Haemorrhage |
2.6% |
| Hyponatraemia |
2.6% |
| Lower Gastrointestinal Haemorrhage |
2.6% |
| Peptic Ulcer |
2.6% |
| Rash Erythematous |
2.6% |
| Renal Failure Acute |
2.6% |
| Small Intestinal Haemorrhage |
2.6% |
| Small Intestinal Ulcer Haemorrhage |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
31.1% |
| Coronary Artery Disease |
16.9% |
| Hypertension |
10.0% |
| Atrial Fibrillation |
7.1% |
| Type 2 Diabetes Mellitus |
5.1% |
| Acute Coronary Syndrome |
3.4% |
| Myocardial Infarction |
3.2% |
| Acute Myocardial Infarction |
2.9% |
| Maternal Exposure Timing Unspecified |
2.7% |
| Drug Use For Unknown Indication |
2.4% |
| Hyperlipidaemia |
2.4% |
| Cerebrovascular Accident Prophylaxis |
2.0% |
| Blood Pressure Increased |
1.7% |
| Deep Vein Thrombosis |
1.5% |
| Diabetes Mellitus |
1.4% |
| Hypercholesterolaemia |
1.4% |
| Pain |
1.4% |
| Cardiac Disorder |
1.2% |
| High Density Lipoprotein Decreased |
1.2% |
| Stent Placement |
1.2% |
|
| Drug Hypersensitivity |
38.1% |
| Upper Gastrointestinal Haemorrhage |
8.6% |
| Gastrointestinal Haemorrhage |
5.8% |
| Renal Failure Acute |
5.0% |
| International Normalised Ratio Increased |
4.3% |
| Thrombosis In Device |
4.3% |
| Gastric Ulcer Haemorrhage |
3.6% |
| Vomiting |
3.6% |
| White Blood Cell Count Increased |
3.6% |
| Urinary Incontinence |
2.9% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
2.2% |
| Haemorrhage Intracranial |
2.2% |
| Malaise |
2.2% |
| Subarachnoid Haemorrhage |
2.2% |
| Subdural Haematoma |
2.2% |
| Transitional Cell Carcinoma |
2.2% |
| Ventricular Septal Defect |
2.2% |
| Weight Decreased |
2.2% |
| Erythema |
1.4% |
| Gouty Arthritis |
1.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
66.8% |
| Hypertension |
5.6% |
| Blood Cholesterol Increased |
2.8% |
| Rheumatoid Arthritis |
2.7% |
| Coronary Artery Disease |
2.3% |
| Drug Use For Unknown Indication |
2.0% |
| Prophylaxis |
1.9% |
| Pain |
1.6% |
| High Density Lipoprotein Decreased |
1.5% |
| Plasma Cell Myeloma |
1.5% |
| Type 2 Diabetes Mellitus |
1.5% |
| Diabetes Mellitus |
1.5% |
| Gastrooesophageal Reflux Disease |
1.4% |
| Atrial Fibrillation |
1.2% |
| Crohn's Disease |
1.1% |
| Blood Triglycerides Increased |
1.1% |
| Cardiac Disorder |
1.0% |
| Depression |
0.9% |
| Low Density Lipoprotein Increased |
0.9% |
| Multiple Myeloma |
0.8% |
|
| Flushing |
21.4% |
| Pruritus |
12.1% |
| Paraesthesia |
7.7% |
| Skin Burning Sensation |
6.1% |
| Weight Decreased |
5.5% |
| Vomiting |
5.4% |
| Death |
3.7% |
| Pneumonia |
3.5% |
| Rash |
3.5% |
| Syncope |
3.5% |
| Myocardial Infarction |
3.4% |
| Weight Increased |
3.4% |
| Pain |
3.3% |
| Pain In Extremity |
3.0% |
| Nausea |
2.6% |
| Drug Ineffective |
2.6% |
| Injection Site Pain |
2.6% |
| Urinary Tract Infection |
2.6% |
| Off Label Use |
2.1% |
| Renal Failure Acute |
2.1% |
|
| Interacting |
| Angina Pectoris |
22.2% |
| Hypertension |
22.2% |
| Acute Myocardial Infarction |
11.1% |
| Atrial Fibrillation |
11.1% |
| Cardiac Failure |
11.1% |
| Coronary Artery Disease |
11.1% |
| Type 2 Diabetes Mellitus |
11.1% |
|
|
